David is chair of the NZ Markets Disciplinary Tribunal and a member of the Takeovers Panel. Directorships include Vero Insurance, Asteron Liability, Harmoney Corp, and NZ Venture Investment Fund. David is a director of specialist corporate law firm Flacks & Wong, having recently retired from Bell Gully after many years as a senior corporate partner.
Hartley has a Masters of Pharmaceutical Chemistry with Distinction (1983) and Doctorate in Pharmacology from Otago University (1989). He published 17 research papers and 2 book chapters prior to entering industry. Before establishing AFT Pharmaceuticals, Hartley had 8 years in multinational pharmaceutical companies in various positions including Medical Director and Sales and Marketing Director.
Prior to co-founding AFT Pharmaceuticals, Marree was a registered nurse at Waikato Hospital. She also worked with Air New Zealand. Marree has been a central figure in building the company since its inception. She has directed developments across key parts of the business, including financial control, regulatory/compliance, brand awareness, international market growth and human resources. She is the company’s Chief of Staff overseeing staff, commercial contracts, and special projects.
Doug Wilson was a New Zealand physician and academic. He joined a major International pharmaceutical company, Boehringer Ingelheim, working in their US subsidiary, becoming their Head of Medical Research and Regulatory Affairs, the interface with FDA, playing a major role in steering 10 drugs through the FDA to the US and global markets. He moved to Head Office in Germany, being responsible for those same functions for worldwide drug development. He chaired the company’s International Medical Committee overseeing the medical aspects of all drugs in development globally, and their Internal Labeling Committee for the drugs on the worldwide market. He was the medical parent of Spiriva, a drug for Chronic Obstructive Pulmonary Disease (COPD) one of the major global killers. The drug last year sold $5 billion. He now consults internationally on new drugs in development, and for pharmaceutical companies.
Jon has lead strategic planning, marketing and restructuring of companies throughout his career. He worked in and headed a multinational pharmaceutical company successfully launching global brands. He created the kiwifruit brand Zespri, and restructured the company into a retail focused operation. He has been a board director on a number of public and private companies, for example a recent a start-up that was developing an antiviral against AIDS where he worked closely with Harvard Medical School who sponsored the clinical trials. He was Deputy Chair of an Australian diagnostic company that had a real time tool for measuring the Hepatitis B virus. He has been involved with AFT Pharmaceuticals Ltd since 2004. He is a member of the Institute of Directors.
Nate Hukill is the President and Chairman of CRG’s investment committee and opened the firm’s Boulder office. Mr. Hukill joined CRG in 2009, bringing more than 16 years of investing experience. Prior to joining CRG, Mr. Hukill was a Portfolio Manager at Highland Capital, where he invested and managed approximately $4.5 billion in the healthcare, consumer products, and technology sectors. Before Highland Capital, Mr. Hukill co-founded a pharmaceutical-focused enterprise software company called OpenQ, Inc. He started his career as a credit investor at Salomon Smith Barney where he managed a portfolio of approximately $800 million.
Jim is Chairman of Assurex Health, and from 2009-2015 served as Executive Chairman and Chief Executive Officer. Previous roles include President of MedPointe Pharmaceuticals, President & CEO of Osiris Therapeutics, General Partner of Healthcare Ventures and Group President of Becton Dickinson.
Hartley has a Masters of Pharmaceutical Chemistry with Distinction (1983) and Doctorate in Pharmacology from Otago University (1989). He published 17 research papers and 2 book chapters prior to entering industry. Before establishing AFT Pharmaceuticals, Hartley had 8 years in multinational pharmaceutical companies in various positions including Medical Director and Sales and Marketing Director.
Malcolm is a qualified Chartered Accountant in the United Kingdom and New Zealand with a wealth of senior corporate governance expertise in the commerce sector including roles in significant public companies as Chief Financial Officer. He has experience in senior positions in public and private companies in pharmaceuticals, beverages, insurance and aged care facilities in Australia and New Zealand. Malcolm has been involved in the AFT board since its foundation. Malcolm is also the CFO for AFT Pharmaceuticals.
Ioana has overall responsibility for the research & development functions of the company. She has more than 20 years experience in the pharmaceutical industry with previous positions, including VP QA & Regulatory Affairs, Head of Vaccine Business Area at FIT Biotech Ltd, and a World Health Organisation adviser performing institutional assessments of National Regulatory Authorities within Central and Eastern Europe. She has coordinated a variety of European FP6 and FP7 funded research grants. In 1999 she was selected as an Expert by the European Health Committee - Council of Europe to participate in the coordinated research study of viral inactivation of labile blood products. She is also a Member of the European QP Association.
Vladimir was born and raised in Macedonia. He holds a Masters degree in Pharmacy from the University of Ljubljana, Slovenia, where he started his career as a pre-clinical researcher before moving to New Zealand. Prior to joining AFT Pharmaceuticlas, Vladimir worked for Douglas Pharmaceuticals in various roles including as QC and QA analyst and regulatory/senior regulatory associate. He joined AFT Pharmaceuticals in 2006 as Regulatory Affairs Manager. Vladimir has responsibility for product registrations in various countries such as New Zealand, Australia, South-East Asia (Malaysia, Singapore, Hong Kong,Philippines) as well as the European Union and USA.
Having worked with brands within the supplement, OTC, Health, and Beauty Channels, her experience has given her the opportunity to drive international brands through a variety of management roles encompassing sales, brand marketing, product sourcing/new product development, and new market expansion.
She has over 20 years’ functional experience with International business, key accounts, sales and marketing teams, with a core focus on brand growth and development within local and International markets such as Australia, US, Asia, UK, and ROW.
Calvin joined AFT in February 2010 and has since led AFT’s Australian team and is responsible for AFT’s business in Australia. Calvin has over 20 years’ experience in the pharmaceutical industry in a diverse range of roles with a pharmacy, medical and specialist focus for brand originator and generic companies including Johnson & Johnson, Janssen Cilag, Arrow and Sigma. Calvin has significant experience in building high-performing sales teams.
Scott joined AFT in March 2013 and is responsible for the OTC sales in New Zealand across all retail channels including pharmacy, supermarkets and petrol & convenience. His role involves the account management, field supervision and trade marketing. Scott has over 20 years’ experience in fast-moving consumer goods in both Australia and New Zealand and has previously held roles with Red Bull and Ferrero Rocher.
Murray joined AFT in October 2011 and has since been responsible for managing the marketing function of AFT, with a primary focus on the Australian and New Zealand markets. His extensive marketing career prior to joining AFT includes roles within Nestlé, Lion Nathan, Bay of Plenty Rugby, Nestlé Purina, New Zealand Lotteries and Fonterra Brands (Tip Top).
